Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox and serial casting for lower limb spasticity after ABI
NCT03903653Phase 2Withdrawn
- Sponsor
- Hamilton Health Sciences
- Start
- Sep 2019
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of botulinum toxin type A in spasticity (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Passive ankle dorsiflexion. Planned start Sep 2019; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT03903653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903653.